Experts challenge the default use of induction chemotherapy. For patients with asymptomatic or low-burden disease, moving directly to a more tolerable, non-chemo maintenance regimen is an emerging and valid consideration, especially given the efficacy of modern maintenance options.

Data from DESTINY-Breast09 shows TDXD plus pertuzumab dramatically improved progression-free survival in first-line metastatic HER2+ breast cancer. This unprecedented efficacy raises new questions about optimal treatment duration and the potential for de-escalated maintenance therapy after induction.

The dramatic results of the PATINA trial reignited conversation around the crucial role and optimal utilization of endocrine therapy in HER2-positive, ER-positive metastatic breast cancer, a topic previously overshadowed by anti-HER2 treatments.

The degree of hormone receptor positivity can guide maintenance strategy. In patients with strongly ER/PR-positive tumors, an endocrine-based approach like the PATINA regimen may be favored. Conversely, in low ER/PR expressing tumors, a more HER2-focused regimen could be more effective.

While the HER2 pathway is the dominant driver for achieving an initial tumor response in HER2+/HR+ disease, targeting the ER pathway is critical for maintaining that response and achieving long-term benefit. This dual-targeting benefit becomes more apparent over extended periods, as seen in the Affinity trial.

DESTINY-Breast09 data shows that complete responses with TDXD+pertuzumab can take 8-10 months to develop. This suggests the regimen is not just a short induction strategy and may offer the greatest benefit for durable remission in lower-burden patients, countering the instinct to de-escalate.

To mitigate long-term toxicity from TDXD, oncologists are proposing an "induction/maintenance" approach. Patients receive TDXD for an initial period to achieve maximal response, then switch to a less toxic maintenance regimen for a "chemotherapy holiday," improving quality of life.

Based on recent trial data, the optimal maintenance strategy for HER2+ metastatic breast cancer differs by subtype. The speaker suggests palbociclib for hormone receptor-positive patients and tucatinib for hormone receptor-negative patients, reflecting a personalized, data-driven treatment approach.

HER2+/ER+ breast cancer is not a single disease. Genomic subtyping reveals distinct biological profiles (luminal A/B, HER2-enriched) with pathologic complete response rates to therapy ranging from just 26% to as high as 61%, signaling the need for tailored treatment strategies.